Abstract
Afatinib is an irreversible oral tyrosine kinase inhibitor, which blocks the receptors from the ErbB family. Its superiority over leading chemotherapy treatments in terms of progression-free survival and overall survival in patients who are carriers of exon 19 deletion in non small cell lung cancers with EGFR mutations has been proven. Its administration has been associated with side affects found with the class of tyrosine kinase inhibitors, the treatment of which includes preventive and symptomatic measures which must be explained to the patient, along with their impact on compliance with the treatment.
Translated title of the contribution | Afatinib, a new drug for lung cancer |
---|---|
Original language | French |
Pages (from-to) | 42-45 |
Number of pages | 4 |
Journal | Actualites Pharmaceutiques |
Volume | 54 |
Issue number | 546 |
DOIs | |
Publication status | Published - 1 May 2015 |
Externally published | Yes |